By a News Reporter-Staff News Editor at Cardiovascular Week -- Research findings on Diet and Nutrition are discussed in a new report. According to news originating from Burlington, Vermont, by NewsRx correspondents, research stated, "Animal studies have shown that vitamin K treatment reduced vascular calcification, but human data are limited. We determined the association between vitamin K status and coronary artery calcium (CAC) progression in the Multi-Ethnic Study of Atherosclerosis by using a case-cohort design."
Our news journalists obtained a quote from the research from the University of Vermont, "Serum phylloquinone (vitamin K1) was measured in 296 participants with extreme CAC progression and 561 randomly selected participants without extreme CAC progression; all subjects had baseline and follow-up CAC measures (mean follow-up: 2.5 y). A serum vitamin K1 concentration was considered low at <1.0 nmol/L (the distribution median). Outcomes were replicated by using post hoc per-protocol analyses of a vitamin K1 supplementation trial. The OR (95% CI) for extreme CAC progression for subjects with low serum vitamin K1 compared with subjects without extreme CAC progression was 1.34 (0.94, 1.90; NS) when adjusted for demographics and confounders. A significant interaction between low vitamin K1 and antihypertension medication use was detected (P = 0.016). Hypertension medication users with low serum vitamin K1 were more likely to have extreme CAC progression than were medication users without extreme CAC progression [OR (95% CI): 2.37 (1.38, 4.09)]. In replication, baseline antihypertensive medication users in the supplementation group had less CAC progression than did those in the control group [adjusted mean SEM of the 3-y CAC change was +5 +/- 20 Agatston units (AU) in the vitamin K1 group (n = 40) and +44 +/- 13 AU in the placebo group (n = 49); P< 0.01] Conclusions: Although the point estimate of our primary analysis suggests low serum vitamin K1 is associated with greater CAC progression, the difference was NS. Low serum vitamin K1 was significantly associated with CAC progression in antihypertension medication users, which, to our knowledge, is a novel finding conditionally replicated by using an independent sample."
According to the news editors, the research concluded: "Intervention trials are needed to determine whether improving serum vitamin K1 reduces CAC progression, especially in hypertensive individuals."
For more information on this research see: Association between circulating vitamin K1 and coronary calcium progression in community-dwelling adults: the Multi-Ethnic Study of Atherosclerosis. American Journal of Clinical Nutrition, 2013;98(1):197-208. American Journal of Clinical Nutrition can be contacted at: Amer Soc Nutrition-Asn, 9650 Rockville Pike, Bethesda, MD 20814, USA (see also Diet and Nutrition).
The news correspondents report that additional information may be obtained from M.K. Shea, Univ Vermont, Coll Med, Dept. of Pathol & Biochem, Burlington, VT, United States.
Keywords for this news article include: Vermont, Burlington, United States, Atherosclerosis, Arteriosclerosis, Diet and Nutrition, Cardiovascular Diseases, North and Central America, Arterial Occlusive Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.